echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Pfizer acquires Arena for US$6.7 billion

    Pfizer acquires Arena for US$6.7 billion

    • Last Update: 2021-12-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 13, Pfizer announced that it had reached a definitive agreement with Arena to acquire all of the latter’s outstanding shares in cash at a price of US$100 per share, with a total transaction value of approximately US$6.
    7 billion
    .


    The board of directors of both companies unanimously agreed on this transaction


    Arena's pipeline products are mainly concentrated in the fields of gastrointestinal diseases, skin diseases and heart diseases
    .


    Including an oral selective sphingosine 1-phosphate (S1P) receptor modulator etrasimod, which has been developed to treat a series of immune inflammatory diseases including gastrointestinal and skin diseases


    Etrasimod is currently conducting two phase III studies for ulcerative enteritis, one phase II/III study for Crohn's disease, one phase III study for atopic dermatitis, and phase II studies for eosinophilic esophagitis and alopecia areata
    .


    On December 5, 2017, Genting Shining won the exclusive development and commercialization rights of etrasimod and ralinepag in Greater China from Arena, with a down payment of 12 million U.


    Arena’s research pipeline also includes two phase II cardiovascular drugs, temanogrel and APD418
    .


    Temanogrel was developed to treat microvascular obstruction secondary to systemic sclerosis and Raynaud's syndrome, and APD418 was developed to treat acute heart failure


    Original link: https://

    https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.